Systemic Lidocaine for Perioperative Analgesia: A Literature Review

Fabrício Tavares Mendonça*, Mariana Campos Reis, Jordana Alvene Aguiar and Luíse Anibal Calvano

Base Hospital of the Federal District, Brazil

Submission: November 17, 2015; Published: December 9, 2015

*Corresponding author: Fabrício Tavares Mendonça, Center of Teaching and Training of Brazilian Society of Anesthesiology, Base Hospital of the Federal District, SMHS101-Special Area, Asa Sul, 70335-900, Tel: +55 61 33151588; Email: fabrício.tavares@me.com

Abstract

Introduction and Background: Intravenous lidocaine has been increasingly used as pain treatment in anesthesiology. The aim of this study was to review the scientific literature on the use of lidocaine for perioperative analgesia, a recent technique and still under study to demonstrate its clinical implications.

Methodology: Data were derived from MD Consult e Clinical Key (1998-2014). A total of 32 articles were selected.

Results and Discussion: Lidocaine acts by changing the excitatory nerve impulse driving; decreasing visceral pain, central sensitization of pain and the immune response. Intravenous lidocaine with good clinical results were used in the dose of preoperative bolus 1.5 to 2 mg.kg-1 followed by continuous infusion 1.5 to 3 mg.kg-1.h-1. Most of clinical trials were in patients undergoing abdominal surgery. It is well-established analgesic, anti-inflammatory and anti-hyperalgesic properties of this local anesthetic; other of its beneficial effects were reduce consumption of volatile anesthetic and opioids, and fasten return of bowel function.

Conclusion: Systemic lidocaine was able to promote great analgesia in surgical procedures. It is a low cost and very convenient alternative on perioperative pain treatment. More clinical controlled studies in different surgical intervention may yield more information about this analgesic approach.

Keywords: Local anesthetics; Pain; Perioperative; Intravenous; Lidocaine

Introduction

Pain is a very common phenomenon on postoperative period and it is often neglected. Pain control is essential for surgical patient assistance, as long as persistence of painful stimuli increase the incidence of complications. Acute pain is related to nociceptive stimuli produced by tissue damage, which results in a group of sensitive, cognitive and emotional experiences, generating autonomic and behavior responses. Acute and persistent painful stimuli may change nervous system’s plasticity leading to its cronification [1,2].

The goal of pain treatment is blocking the generation, transmission, perception and sensation of nociceptive stimuli in different levels of peripheral and central nervous system [1]. This reduces perioperative morbidity, favors surgical treatment result, reduces hospital expenses and decreases postoperative chronic pain risk [3,4].

Nevertheless, many patients submitted to surgical procedures go through moderate to strong pain on postoperative period, indicating that despite of the development of new medications and implementation of different analgesic techniques, postoperative pain remains misdiagnosed and mistreated [5].

Opioid analgesics are commonly used in clinical practice for perioperative pain treatment. However, its use is related to many side effects, as respiratory depression, nausea, vomit, drowsiness, pruritus, urinary retention, constipation, hyperalgesia and immunologic function compromise [6]. Therefore, alternative techniques and medications have been used as substitute of opioid for analgesia, that is, where well fits the systemic intravenous infusion of lidocaine, local anesthetic widely used on anesthesiology practice [6-8].

Studies showed that the intraoperative use of lidocaine considerably diminished postoperative pain, but when administered only on postoperative period it did not have
analgesic effective results. The mechanisms of analgesia of this local anesthetic on surgical trauma include neuronal transmission blockage at the place of injury, reducing neurogenic response and systemic anti-inflammatory intrinsic activity. Lidocaine’s analgesic property can persist even after the decreasing of its plasmatic levels, which corroborates the nervous conduction blockage theory [6,8-13].

Intraoperatively, aside from analgesia, lidocaine also promotes reduction of inhaled anesthetics and opioid consumption, earlier return of bowel function, diminished production of interleukines and reduction airway reactivity [9]. This local anesthetic has important anti-inflammatory properties: reduces cytokine release in vitro and in vivo by inhibiting neutrophile activation [10,11].

There are few studies with systemic lidocaine use during the perioperative period and intravenous injection of local anesthetic is still surprising for many medical professionals, what aroused interest in the subject chosen for this review.

Methodology

We performed a critical review of literature from March 2011 to March 2014. Articles found on the data base MD Consult e Clinical Key and published from 1998-2014 were considered. We used free text and MeSH terms - local anesthetics, pain, perioperative, intravenous, and lidocaine - for articles in Portuguese and English language. Werecruited additional studies from bibliographies of retrieved trials and previous reviews. We excluded data from abstracts, case reports and letters. Of the 463 articles screened, 431 were excluded. A total of 32 articles were selected, and these were review of the pharmacological aspects of lidocaine and clinical trials using this local anesthetic for intravenous continuous infusion perioperatively.

Results and Discussion

Pharmacological Properties

Lidocaine has been used for several indications such as regional anesthesia, antiarrhythmic, on peripheral and central pain treatment, and as adjuvant on postoperative acute pain treatment including opioid refractory cases [8]. Recent researches have shown its mechanism in a more detailed way, emphasizing its multimodal action. 

Lidocaine or 2-(Diethylamino)-N-(2,6-dimethylphenyl)-acetamide is a weak base, with a pKa of 7,9. In general, local anesthetics with a pKa that approximates physiologic pH have a higher concentration of non-ionized base resulting in a faster onset. Lidocaine itself has a great amount of lipid soluble and non-ionized local anesthetic on plasma, therefore it has the property of easily penetrating the neural sheath and axonal membrane [8,13].

Lidocaine and its metabolites monoethylglycinexylidide (MEGX), glycineylidide, and N-ethylglycine, interacts with peripheral and central voltage-gated sodium channel on intracellular face of membrane blocking the start and conduction of neural impulses potential [8].

When intravenously administered, this local anesthetic is first distributed to highly perfused organs such as brain, heart, lung, liver and kidney, followed by less perfused tissues like skin, skeletal muscles, fat and peripheral organs. Its volume of distribution is great, as 60% of its molecules are bind to plasma protein [12].

Close to 40% of systemic lidocaine is extracted at the first stage of the process at the lungs, highly reducing the intoxication probability after accidental intravascular injection [12]. Its elimination half-life is of 1,5 to 2h and about 90% of the drug is metabolized by the liver, at the microsomal enzyme system (cytochrome P450). Its degradation pathway is mainly the conversion to monoethylglycinexylidide (MEGX) by oxidative N-de-ethylation followed by hydrolysis to 2,6-xyldline. Those metabolites have active properties and have been related to toxicity cases of systemic local anesthetic after repeated bolus and continuous infusion. The lidocaine excretion occurs in the kidneys through an early renal elimination, from 8 to 17 minutes, and a late phase elimination of 87 to 108 minutes [12].

Mechanism of Action

Lidocaine’s intravenous administration has peripheral and central action, and involves several mechanisms: sodium channel and NMDA (N-methyl-D-aspartate) receptors block, glycnergic action and substance P decrease. In low concentration, it inhibits primary afferent fibers abnormal activity, mainly at C fibers; causes sympathetic block, vasodilation and breaks the sequence of action that perpetuates the painful stimulus. In therapeutic plasma concentrations (1,5 a 5 µg.mL-1), it diminishes the hyperexcitability without affecting nerve conduction; promotes reduction of medular sensitivity and post-synaptic despolarization NMDA and neurocinine mediated; also reduces medullary neuron activity [13,14].

Systemic lidocaine has antinociceptive effects in which glycnergic mechanisms might be involved. Synaptic levels of glycine, an important inhibitory neurotransmitter, is regulated by glycine transporters (GlyT1 and GlyT2). In a study that analysed GlyT1’s function in rats astrocytes and frogs oocytes, the local anesthetic lidocaine itself, reduced glycine uptake only at toxic concentrations. However, the metabolites MEGX, glycineylidide, and N-ethylglycine significantly reduced glycine uptake at a clinically relevant concentration increasing extracellular glycine levels. This increasing of the extracellular level of glycine at the synaptic cleft via blockade of GlyT1, inhibits the pathologically increased conduction of excitatory signs in glutamate and NMDA receptors responsible for the painful stimulus, assuring antinociceptive effect [14].

Besides of acting at voltage-gated sodium channels, studies showed that lidocaine yet has effects over G protein-gated, NMDA and calcium-activated potassium channels receptors, through
what it alters the excitatory impulse conduction over A-delta and C fibers, modifying also visceral pain sensitivity, central sensitization and immunological response resulting from pain stimuli [2,15,16].

In other hand, this local anesthetic seems to indirectly block NMDA receptors through protein kinase C inhibition, with impact over postoperative hiperalgiesia and opioids tolerance [17].

When lidocaine is used systematically, there is an increasing of acetylcholine levels at the liquor, exacerbating pain sensitivity inhibition via descending inhibitory pain pathways, with consequent analgesia. Related to that, is likely that lidocaine’s connection with M3 muscarinic, glycine receptors inhibition and endogenous opioid releasing corroborates to its analgesic final effect.

Reduction of inflammatory response to ischemia and diminution of endothelial cytokine-induced tissue damage through adenosine triphosphate release and potassium channel is something that also happens. It is wondered that systemic lidocaine may reduce myocardial ischemia, vasoconstriction and trombose mediator thromboxane A2 production by directly interacting with the endothelial membrane [8,13].

Lidocaine interferes in a few inflammatory processes like oxygen free radicals production, lisosomne neutrofile sensitization and degranulation, and cytokine releasing at macrophages and glia cells. It also reduces cytokine induced cellular damage through mitochondrial potassium channels adenosine triphosphate sensitive [18,19].

In summary, the mechanism of action of this local anesthetic is capable of promoting clinically relevant relief of spontaneous pain, dysesthesia, hiperalgiesia and mechanicaldodynia through various pathways [13,20].

Toxicity

As systemic lidocaine’s circulation level increases, the signs and symptoms of its effects over central nervous and cardiovascular systems are manifested.

Lidocaine’s plasma concentrations below 5 µg.mL⁻¹ causes analgesia and inhibition of cortical motoneurons, justifying its anticonvulsive action [20]. In higher seric levels, from 5 to 10 µg.mL⁻¹, there is perioral paresthesia, metallic taste, dizziness, diplopia, tinnitus, drowsiness, confusion, agitation, muscle twitching and seizure. The last one happens with doses between 10 and 15 µg.mL⁻¹ [13].

Many times, seizure is the first sign of severe local anesthetic toxicity. It occurs because of inhibition of the inhibitory neurons through GABA (gamma-aminobutyric acid) receptors stimulation at central amygdala. The seizure usually happens when lidocaine’s plasmatic concentration is over 8 µg.mL⁻¹, although it can arise in lower concentrations in hipercarbia situations [15]. Yet, cardiovascular toxicity goes with depression of myocardial automatism in lidocaine doses higher than 25 µg.mL⁻¹. It manifests as bradycardia, prolonged PR interval and wide QRS complex, conduction block, progressive hypotension and ventricular arrhythmias. Severe cardiac toxicity demands almost three times the seric concentration that causes seizures.

The treatment of the toxicity must include clinical support with oxygenation, hydrating and use of vasopressors, inotropic, antiarrhythmic and anticonvulsivants according to clinical needs [21]. Implementing lipid therapy is indicated to prevent cardiovascular collapse based on clinical severity and rate of progression of symptoms, since only a fraction of patients will progress to severe toxicity to local anesthetics [22].

Clinical Studies

Systemic lidocaine used in continuous infusion on perioperative period has analgesic, antihiperalgesic and antiinflammatory properties, which makes it capable of reducing intra and postoperative drugs consumption and patients hospital stay [16,19]. Its effects are mostly pronounced with intraoperative infusion followed by postoperative infusion of intravenous lidocaine for days and even weeks, that is long time infusion and over the drug’s plasmatic half-life applicability. This indicates that lidocaine’s action is not limited to voltage-gated sodium channels but it is extended to other goals, and suggests prevention of hypersensitivity at the central and peripheral nervous system regularly started and kept by painful stimuli [6,18].

Lidocaine’s intravenous most appropriate dose for treating post operative pain in a more efficient way is not yet defined. Some authors have shown that low doses like in between 1,5 e 3 mg.kg⁻¹.h⁻¹ (plasmatic levels lower than 5 µg.mL⁻¹) reduce pain after surgical procedures with lower incidence of side effects and without influence at nerve conduction [15,16,18,23].

Grigoras and colleagues, made a prospective, double blinded, controlled clinical trial in 36 patients Asa I e II, submitted to total mastectomy with or without complete axillary dissection. Of those, 17 received intravenous infusion of lidocaine 1,5 mg.kg⁻¹ in 10 min immediately after orotracheal intubation, followed by 1,5 mg.kg⁻¹.h⁻¹ stopped 60 min after skin closure. The 19 other patients received saline solution under the same scheme. All patients were evaluated for acute pain and postoperative pain persisting after three months, besides the extension of secondary hiperalgesia area. As a result, there was that morfine consumption was alike on both groups during the first 4h postoperative; plasmatic lidocaine levels were in the adequate average considering the drug’s toxicity; lower incidence of postoperative persistent pain and smaller extension of hiperalgesia area at the surgical incision at the systemic lidocaine continuous infusion group [24]. In other words, this study brought to evidence the analgesic and antihiperalgesic properties of the systemic use of lidocaine via venous infusion perioperatively, offering better postoperative pain control, what may also be a way of preventing pain cronification [2].
Koppert [25] and collaborators demonstrated that patients who received lidocaine via venous infusion in low doses intra and postoperatively (bolus of 1.5 mg.kg⁻¹ for about 30 minutes before surgical incision, followed by continuous infusion of 1.5 mg.kg⁻¹.h⁻¹ until 60 minutes after end of surgery) felt less pain at mobilization and needed less amount of morphine at the first 72h after abdominal surgery compared to patients that didn't receive lidocaine. As this effect of reducing opioid needs was more evident at the third day of postoperative period, lidocaine may have a truly preventive analgesic activity avoiding pain sensibilization and its consequent central induced hyperalgesia in a clinically relevant way [17].

In a clinical trial made by Kaba and colleagues, lidocaine was used in patients undergoing laparoscopic colectomy administered as bolus of 2 mg.kg⁻¹ pre-incisional and kept as continuous infusion of 3 mg.kg⁻¹.h⁻¹ till the end of the procedure providing significant relief of postoperative pain and fatigue, faster return of bowel function, lower volatile anesthetic and opioid consumption, reduction of interleukine production (IL-1α, IL-6 e IL-8) and of the hospitalization time [16].

Heroeder and collaborators achieved similar results in a group of 60 patients submitted to colorectal surgery that refused or had contraindications to epidural catheter. It was infused intravenously lidocaine bolus of 1.5 mg.kg⁻¹ before induction of anesthesia, followed by continuous infusion of 2 mg.min⁻¹ till 4 hours after surgery. Lidocaine significantly decreased return of bowel function period and reduced time of hospital stay in one day. Besides of that, it was found important attenuation of increasing of inflammatory markers suggesting an anti-inflammatory activity and a potential modulating effect over inflammatory response to surgical stress. There was no difference in pain evaluation criteria. Nevertheless, systemic use of lidocaine may be a very convenient and low cost alternative to get analgesia and satisfactory anesthetic outcomes in patients that cannot go through epidural anesthesia [26].

Marret and colleagues performed a metanalysis that selected 8 randomized, double-blinded clinical studies that evaluated a total of 320 patients undergone exclusively to abdominal surgeries. Of those patients, 161 received intravenous infusion of lidocaine and 159 received placebo. In 7 of the 8 studies lidocaine was administered in bolus of 1.5 a 2 mg.kg⁻¹ initiated before surgical incision, followed by continuous infusion at the same dose till the end of surgery or 24h postoperative. In the 8 studies evaluated, the result of systemic lidocaine’s use was reduction of postoperative paralytic ileus duration, pain, nausea and vomit and time of hospital stay [27].

Saadawy and collaborators made a double-blinded study in 120 patients submitted to laparoscopic cholecystectomy using the lidocaine dose of bolus of 2 mg.kg⁻¹ followed by continuous infusion of 2 mg.kg⁻¹.h⁻¹. There was lower need of morphine use at the second postoperative hour. The lidocaine group had lower scores of abdominal pain at rest and during coughing episodes, with 2, 6 e 12h postoperative, and faster recovery of bowel function. At the end of lidocaine’s infusion it’s plasmatic levels were of 2,6µg.mL⁻¹ [28].

Yardeni and colleagues examined 65 patients undergoing hysterectomy under general anesthesia. The group that used lidocaine had 2 mg.kg⁻¹ bolus at anesthetic induction followed by 1.5 mg.kg⁻¹.h⁻¹ in continuous infusion till end of surgery. This group presented lower scores of pain at rest and during coughing episodes at the first 8h postoperative, and attenuation of immunologic response due to the lower production of cytokines pro and anti-inflammatory (IL-6 e IL-1ra respectively). This indicates that perioperatively use of systemic lidocaine improves acute pain control in immediate postoperative period and reduces surgical stress-induced immune response [29].

Wongyingsinn and collaborators evaluated 60 patients undergoing colorectal laparoscopic surgery in which it was used systemic lidocaine 1,5 mg.kg⁻¹ infusion (maximum of 100 mg) in anesthetic induction, maintained as 2 mg.kg⁻¹.h⁻¹ infusion until the end of the surgical procedure and 1 mg.kg⁻¹.h⁻¹ at the first 48h postoperative. The authors compared epidural thoracic analgesia with general anesthesia and observed that systemic lidocaine produced similar benefits to return of bowel function and analgesia’s global quality on patients submitted to colonic resection. There was no statistical difference at the time of hospital stay between the evaluated groups [30].

Swenson and collaborators studied 45 patients undergone to colon resection open surgery and compared epidural thoracic analgesia using bupivacaine 0,125% and hidromorfone 6mcg.mL⁻¹ 10mL/h for 1h until the end of surgery, and general anesthesia with lidocaine bolus at induction with approximately 1,5 mg.kg⁻¹ and maintenance according to the scheme: 1 mg.min⁻¹ in < 70 kg patients and 2 mg.min⁻¹ in ≥70 kg patients. The authors didn’t notice any difference between the groups related to return of bowel function, time of hospital stay and postoperative pain control, suggesting once more that intravenous infusion of lidocaine may be an effective alternative to epidural therapy in patients that neuroaxial anesthesia is refused or contraindicated [31].

Kang and colleagues examined 48 patients submitted to gastrectomy under general anesthesia with intravenous lidocaine in bolus dose of 1,5 mg.kg⁻¹ at induction and same dose incontinuous infusion until the end of surgery. This technique significantly diminished the opioid postoperative consumption and time of hospital stay, although this study hasn’t shown any improvement of pain levels and return of bowel function [32].

Most recently, KyongTae and collaborators evaluated the effect of intravenous lidocaine infusion on postoperative pain at lumbar microdiscectomy at a prospective, randomized, double-blinded controlled clinical trial with 51 patients. The control group received lidocaine infusion pre and intraoperative in 1.5
mg.kg$^{-1}$ bolus followed by 2 mg.kg$^{-1}$.h$^{-1}$ infusion until the end of surgical procedure, and placebo infusion of saline solution. The lidocaine group had statistically relevant results with lower pain scale scores and lower opioid consumption at first 48h postoperatively and in the total amount, smaller frequency of patient controlled analgesia button push, shorter length of time of hospital stay and higher patient's satisfaction scores. That is, systemic lidocaine reduced the painful perception during microdiscectomy, consequently diminishing opioid consumption and postoperative pain intensity, which contributed to a shorter hospital stay [33] (Table 1).

**Table 1: Effects of intravenous lidocaine infusion according to study time.**

<table>
<thead>
<tr>
<th>Reference</th>
<th>Type of Study</th>
<th>Sample Group Profile</th>
<th>Lidocaine IV Infusion</th>
<th>Effects</th>
</tr>
</thead>
<tbody>
<tr>
<td>Dirks et al.</td>
<td>RCT (Randomized Controlled Trial)</td>
<td>The heat/capsaicin sensitization model of experimental pain in 24 volunteers</td>
<td>lidocaine 2% bolus 2 mg/kg, then infusion 3 mg/kg/h</td>
<td>Systemic lidocaine showed a selective effect on secondary hyperalgesia.</td>
</tr>
<tr>
<td>Koppert et al.</td>
<td>RCT</td>
<td>12 volunteers capsaicin injection sensitization model</td>
<td>lidocaine 2% bolus injection of 2 mg/kg in 10 min followed by an intravenous infusion of 2 mg/kg/h for another 50 min</td>
<td>Systemic lidocaine reduces pin-prick hyperalgesia by a central mode of action.</td>
</tr>
<tr>
<td>Koppert et al.</td>
<td>RCT</td>
<td>40 patients undergoing major abdominal surgery</td>
<td>lidocaine 2% bolus 1.5 mg/kg in 10 min followed by 1.5 mg/kg/h (infusion started 30 min before skin incision and was stopped 1 h after the end of surgery)</td>
<td>Patients who received lidocaine reported less pain during movement and needed less morphine during the first 72 h after surgery.</td>
</tr>
<tr>
<td>Finnerup et al.</td>
<td>RCT</td>
<td>24 spinal cord injury patients with neuropathic pain</td>
<td>5 mg/kg lidocaine 2% infused over 30 min</td>
<td>Lido inae reduced neuropathic pain at and below the level of injury irrespective of the presence or absence of evoked pain.</td>
</tr>
<tr>
<td>Kuo et al.</td>
<td>RCT</td>
<td>60 patients submitted to colonic surgery</td>
<td>IV and epidural: Lidocaine 2% bolus 2 mg/kg (infusion started 30 min before surgery and maintained throughout procedure)</td>
<td>Thoracic epidural analgesia with lidocaine had better pain relief, lower opioid consumption, earlier return of bowel function and lesser production of cytokines than IV lidocaine during 72 h after colonic surgery.</td>
</tr>
<tr>
<td>Wu et al.</td>
<td>RCT</td>
<td>100 patients scheduled for elective laparoscopic colectectomy</td>
<td>Lidocaine 2% 3 mg/kg/h (infusion started 30 min before skin incision and maintained throughout procedure)</td>
<td>Additional effect on pain relief and a synergistic effect on recovery of bowel function when IM dextromethorphan was combined with IV lidocaine after laparoscopic colectomy.</td>
</tr>
<tr>
<td>Kaba et al.</td>
<td>RCT</td>
<td>40 patients scheduled to undergo laparoscopic colectomy</td>
<td>Lidocaine 2% bolus injection of 1.5 mg/kg at induction of anesthesia, then infusion of 2 mg/kg/h intraoperatively and 1.33 mg/kg/h for 24 h postoperatively</td>
<td>Intravenous lidocaine improves postoperative analgesia, fatigue, and bowel function after laparoscopic colectomy. These benefits are associated with a significant reduction in hospital stay.</td>
</tr>
<tr>
<td>Herroeder et al.</td>
<td>RCT</td>
<td>60 patients undergoing colorectal surgery, not willing or unable to receive an epidural catheter</td>
<td>Lidocaine 2% bolus 1.5 mg/kg before induction of anesthesia followed by a continuous infusion of 2 mg/min until 4 h postoperatively</td>
<td>Lido inae significantly accelerated return of bowel function and shortened length of hospital stay by one day. Elevated plasma levels of IL-6, IL-8, C3a, IL-1ra, CD11b, L- and P-selectin, and platelet-leukocyte aggregates were significantly attenuated by systemic lidocaine.</td>
</tr>
<tr>
<td>Marret et al.</td>
<td>Meta-analysis</td>
<td>8 RCT comparing continuous intravenous lidocaine infusion during and after abdominal surgery with placebo (total of 320 patients)</td>
<td>In seven of the eight RCTs, a lidocaine 2% bolus (1.5–2 mg/kg) was given before surgical incision followed by a continuous infusion until the end of operation or 24 h after it</td>
<td>Intravenous lidocaine administration decreased the duration of 8 h of hospital stay, postoperative pain intensity at 24 h after operation and vomiting.</td>
</tr>
</tbody>
</table>
Yardeni et al. [29] | RCT | 65 female patients scheduled for transabdominal hysterectomy | Lidocaine 2% IV (bolus injection of 2 mg/kg lidocaine through the numbered syringe followed by a continuous IV infusion of 1.5 mg/kg/h until the end of surgery) + patient-controlled epidural analgesia | There was significantly less ex-vivo production of IL-1ra and IL-6 in the group lidocaine + patient-controlled epidural analgesia.  
Lidocaine reduced anesthetic requirements, pain scores and morphine consumption relative to the control group.  
Lidocaine was associated with earlier return of bowel function.  
Thoracic epidural analgesia provided better analgesia in patients undergoing rectal surgery. Time out of bed, dietary intake and hospital stay were similar.  
No differences were observed between lidocaine IV and epidural analgesia groups in terms of return of bowel function, duration of hospital stay, and postoperative pain control.  
Intraoperative IV low-dose lidocaine infusion decreased the incidence and severity of persistent postsurgical pain after breast cancer surgery. Prevention of the induction of central hyperalgesia is a potential mechanism.  
Intraoperative IV low-dose lidocaine infusion decreased opioid consumption and hospital length of stay after gastrectomy. No differences were noted between the groups in pain intensity or duration of ileus.  
In general, this literature review analysis showed that in most of the clinical studies selected systemic lidocaine for perioperative analgesia was used in the dose of 1.5 a 2 mg/kg in bolus at anesthetic induction followed by continuous infusion of 1.5 a 3 mg/kg/h intraoperative until the end of the surgical procedure. It was seen that lidocaine, in this therapeutic form, produces clinically relevant analgesia intra and postoperatively, prevents chronic pain, reduces consumption of volatile anesthetics and opioid, significantly accelerates return of bowel function and, this way, reduces time of hospital stay. Yet, it came to evidence that lidocaine causes significant attenuation of production of various inflammatory markers suggesting an anti-inflammatory activity and potential mechanism of modulation of surgical stress-induced inflammatory response. All these findings show that intravenous continuous infusion of lidocaine in the perioperative period may be a convenient and low cost alternative to achieve analgesia and satisfactory anesthetic outcomes in patients that cannot undergo epidural anesthesia.  
Conclusion  
In the past years, the use of systemic lidocaine as analgesic perioperative technique gained more visibility. This literature review verified that the dose of intravenous lidocaine with good clinical outcomes was bolus of 1,5 a 2 mg/kg in the anesthetic induction followed by continuous infusion of 1.5 a 3 mg/kg/h intraoperative until the end of the surgical procedure.  
It was concluded that the recent studies prove the efficiency of the use of this local anesthetic on the perioperative period because of its properties of acute pain relief and chronic pain.
prevention, besides of reducing the consumption of anesthetics and promoting early return of bowel function, accelerating hospital discharge.

This way, systemic lidocaine should be seen as one more option of analgesia on anesthesiologists antalgic therapy wide range of medication possibilities. Its administration is low cost compared to other medications, also more achievable and clinically safe in posologic well established limits, with specific indication and good alternative to promote efficient analgesia in patients that have any contraindication to neuroaxial anesthesia. The effort of elaborating more controlled clinical studies with the use of systemic lidocaine in different surgical intervention may bring more relevant information about this analgesic approach.

References
